While 2023 net revenue was 26% lower than that peak, as interest rates and economic uncertainty increased, the firm appears to have stabilized and looks poised for a return to high-single-digit ...

Investing.com -- Evercore ISI added Wendy’s Co to its Tactical Outperform list ahead of the company’s investor day on March 6 ...

Shares of Vera Therapeutics (VERA) sold off about 20% on Friday following news in competitor Otsuka’s 2024 earnings presentation that the ...

Analysts say NVIDIA (NASDAQ: NVDA) is a buy ahead of earnings because the results will be robust, high-double-digit growth is ...

Evercore ISI analyst David Palmer is adding Wendy’s (WEN) to the firm’s “Tactical Outperform List” as the firm sees upside heading into Wendy’s ...

Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss the markets, Meta's historic winning ...

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

In the lead-up to Nvidia Inc.’s NVDA forthcoming earnings report after market close on Feb.26, Evercore ISI suggests that it is a good buying opportunity amid strong fundamentals. What Happened: In a ...

Rich Ross, head of technical analysis at Evercore ISI, said that a breakout to an all-time high in the S&P 500 ( SP500 ), ( ...